BlackRock, Inc. (LCTX) discloses 5.3% beneficial ownership in Lineage Cell

Rhea-AI Filing Summary

BlackRock, Inc. reports beneficial ownership of common stock of Lineage Cell Therapeutics Inc. BlackRock and certain of its business units beneficially own 13,185,489 shares of Lineage common stock, representing 5.3% of the class.

BlackRock has sole voting power over 13,024,110 shares and sole dispositive power over 13,185,489 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Lineage’s outstanding common shares.

Key Figures

Beneficial ownership: 13,185,489 shares Percent of class: 5.3% Sole voting power: 13,024,110 shares +2 more

5 metrics

Beneficial ownership 13,185,489 shares Common stock of Lineage Cell Therapeutics Inc reported by BlackRock, Inc.

Percent of class 5.3% Portion of Lineage Cell Therapeutics common stock class beneficially owned by BlackRock, Inc.

Sole voting power 13,024,110 shares Shares of Lineage Cell Therapeutics over which BlackRock has sole power to vote

Sole dispositive power 13,185,489 shares Shares of Lineage Cell Therapeutics over which BlackRock has sole power to dispose

Filing date signature 07/29/2026 Date signed by Managing Director Spencer Fleming on the Schedule 13G

Key Terms

beneficially owned, sole voting power, sole dispositive power, parent holding company, +1 more

5 terms

beneficially owned financial

"this reflects the securities beneficially owned, or deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 13,024,110.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 13,185,489.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

parent holding company regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 03:22 PM Accepted by SEC EDGAR 07/29/2026 - 03:19 PM Learn about SEC filing dates

FAQ

What stake does BlackRock, Inc. report in Lineage Cell Therapeutics Inc (LCTX)?

BlackRock reports beneficial ownership of 13,185,489 shares of Lineage Cell Therapeutics common stock, representing 5.3% of the outstanding class, based on its Schedule 13G filing for the issuer’s common stock.

How much voting power does BlackRock have in LCTX according to the Schedule 13G?

BlackRock has sole voting power over 13,024,110 shares of Lineage Cell Therapeutics and no shared voting power, as disclosed under the ownership section of the Schedule 13G filing.

What dispositive power over LCTX shares does BlackRock report?

BlackRock reports sole dispositive power over 13,185,489 shares of Lineage Cell Therapeutics common stock and no shared dispositive power, meaning only it can decide how those reported shares are disposed of.

Who ultimately benefits from BlackRock’s LCTX share holdings?

The filing states that various persons have the right to receive dividends or sale proceeds from Lineage Cell Therapeutics shares managed by BlackRock, but no one person’s interest exceeds five percent of the total outstanding common shares.

What is the nature of BlackRock’s filing for LCTX, and which entities are included?

The Schedule 13G reflects securities beneficially owned, or deemed beneficially owned, by certain business units of BlackRock and its subsidiaries; other BlackRock units with disaggregated reporting are not included in this ownership report.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lineage Cell Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

53566P109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 53566P109

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 13,024,110.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 13,185,489.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,185,489.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lineage Cell Therapeutics Inc
(b)	Address of issuer's principal executive offices: 2173 SALK AVENUE, SUITE 200 CARLSBAD CA 92008
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 53566P109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 13185489
(b)	Percent of class: 5.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 13024110
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 13185489
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Lineage Cell Therapeutics Inc. No one person's interest in the common stock of Lineage Cell Therapeutics Inc is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/29/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7